Sunday, 2 November 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 02 November 2025
News

Hot market on the slide

Posted 30 October 2025 AM

The global atrial fibrillation (AF) market is about to take a big hit, thanks largely to generic sales of novel oral anticoagulants (NOACs), according to analytics company GlobalData.

AF sales in the eight major markets (8MM): the US, France, Germany, Italy, Spain, the UK, Canada and Japan will fall from US$14.5 billion in 2022 to US$10.5 billion in 2032, according to a GlobalData forecast, equating to a negative compound annual growth rate (CAGR) of 3.2 per cent.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (3)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.